Recent publications of BOPA members

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then please contact the research committee so that we can disseminate these to the membership.

Asher S, Shah Raakhee, Ings S, Horder J, Newrick F, Nesr G, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N. Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma. Br J Haematol. 2023 Sep;202(6):1224-1227 https://doi.org/10.1111/bjh.18990

Alkesh Patel, Francesco Perrone, Darren M. Ashcroft, Nicola Flaum, Natalie Cook, Silvia Riva, Cross-cultural adaptation of the PROFFIT Instrument to measure financial toxicity in people living with cancer within a UK population, Journal of Cancer Policy, Volume 38, 2023  https://doi.org/10.1016/j.jcpo.2023.100440

Tew Alice, Khoja L, Pallan L, Steven N. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. Journal of Oncology Pharmacy Practice. 2023;29(5):1163-1171. doi http://10.1177/10781552221103548

Awan Sidra, Bharucha P, Steventon L, et al. Out-of-hours admissions in patients treated with immune checkpoint inhibitors and their primary management with steroids. Journal of Oncology Pharmacy Practice. 2023;0(0). doi http://10.1177/10781552231207271

Kobat, H., Elkonaissi, Islam., Foreman, Emma., Davidson, M., Idaikkadar, P., O’Brien, M., & Nabhani-Gebara, Shereen. (2023). Smoking, diabetes mellitus and previous cardiovascular disease as predictors of anti-cancer treatment-induced cardiotoxicity in non-small cell lung cancer: A real-world study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.09.007